bioAffinity Technologies Secures Approximately $4 Million in Direct Financing
bioAffinity Technologies announced a registered direct offering of common stock and a concurrent private placement totaling approximately $4 million. The proceeds are intended to bolster the company's research and development efforts.
Biotechnology firm bioAffinity Technologies has announced a financing arrangement valued at approximately $4 million. WallachBeth Capital LLC acted as the exclusive placement agent for the registered direct offering of common stock and the concurrent private placement.
The direct financing is aimed at supporting bioAffinity Technologies' ongoing research and development initiatives. The company focuses on developing non-invasive healthcare solutions, particularly in the area of cancer diagnostics.
The funds will assist the company in advancing its technology for clinical trials and potential future commercialization efforts. The financing is being conducted under Nasdaq rules and is priced at-the-market.
Further details regarding the terms of the financing and its expected impact on the company's future operations are anticipated. bioAffinity Technologies is listed on the Nasdaq under the symbols BIAF and BIAFW.